Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
Aim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in predicting the prognosis and therapeutic efficacy in hepatocellular carcinoma (HCC) patients a...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/17/4348 |
| _version_ | 1797582710971039744 |
|---|---|
| author | Kazunari Tanaka Kunihiko Tsuji Atsushi Hiraoka Toshifumi Tada Masashi Hirooka Kazuya Kariyama Joji Tani Masanori Atsukawa Koichi Takaguchi Ei Itobayashi Shinya Fukunishi Toru Ishikawa Kazuto Tajiri Hironori Ochi Hidenori Toyoda Chikara Ogawa Takashi Nishimura Takeshi Hatanaka Satoru Kakizaki Noritomo Shimada Kazuhito Kawata Atsushi Naganuma Hisashi Kosaka Tomomitsu Matono Hidekatsu Kuroda Yutaka Yata Hideko Ohama Fujimasa Tada Kazuhiro Nouso Asahiro Morishita Akemi Tsutsui Takuya Nagano Norio Itokawa Tomomi Okubo Taeang Arai Keisuke Yokohama Hiroki Nishikawa Michitaka Imai Yohei Koizumi Shinichiro Nakamura Hiroko Iijima Masaki Kaibori Yoichi Hiasa Takashi Kumada |
| author_facet | Kazunari Tanaka Kunihiko Tsuji Atsushi Hiraoka Toshifumi Tada Masashi Hirooka Kazuya Kariyama Joji Tani Masanori Atsukawa Koichi Takaguchi Ei Itobayashi Shinya Fukunishi Toru Ishikawa Kazuto Tajiri Hironori Ochi Hidenori Toyoda Chikara Ogawa Takashi Nishimura Takeshi Hatanaka Satoru Kakizaki Noritomo Shimada Kazuhito Kawata Atsushi Naganuma Hisashi Kosaka Tomomitsu Matono Hidekatsu Kuroda Yutaka Yata Hideko Ohama Fujimasa Tada Kazuhiro Nouso Asahiro Morishita Akemi Tsutsui Takuya Nagano Norio Itokawa Tomomi Okubo Taeang Arai Keisuke Yokohama Hiroki Nishikawa Michitaka Imai Yohei Koizumi Shinichiro Nakamura Hiroko Iijima Masaki Kaibori Yoichi Hiasa Takashi Kumada |
| author_sort | Kazunari Tanaka |
| collection | DOAJ |
| description | Aim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in predicting the prognosis and therapeutic efficacy in hepatocellular carcinoma (HCC) patients administered atezolizumab plus bevacizumab (Atez/Bev) as first-line treatment. Materials/Methods: The study period covered September 2020 to December 2022 and involved 371 HCC patients treated with Atez/Bev. The values of the TMs AFP, AFP-L3, and DCP were measured upon introducing Atez/Bev. Elevations in the values of AFP (≥100 ng/mL), AFP-L3 (≥10%), and DCP (≥100 mAU/mL) were considered to indicate a positive TM. The number of positive TMs was summed up and used as the TM score, as previously proposed. Hepatic reserve function was assessed using the modified albumin–bilirubin grade (mALBI). Predictive values for prognosis were evaluated retrospectively. Results: A TM score of 0 was shown in 81 HCC patients (21.8%), 1 in 110 (29.6%), 2 in 112 (29.9%), and 3 in 68 (18.3%). The median overall survival (OS) times for TM scores 0, 1, 2, and 3 were not applicable [NA] (95% CI NA-NA), 24.0 months (95% CI 17.8-NA), 16.7 months (95% CI 17.8-NA), and NA (95% CI 8.3-NA), respectively (<i>p</i> < 0.001). The median progression-free survival (PFS) times for TM scores 0, 1, 2, and 3 were 16.5 months (95% CI 8.0-not applicable [NA]), 13.8 months (95% CI 10.6–21.3), 7.7 months (95% CI 5.3–8.9), and 5.8 months (95% CI 3.0–7.6), respectively (<i>p</i> < 0.001). OS was well stratified in mALBI 1/2a and mALBI 2a/2b. PFS was well stratified in mALBI 2a/2b, but not in mALBI 1/2a. Conclusions: The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as first-line treatment. |
| first_indexed | 2024-03-10T23:26:23Z |
| format | Article |
| id | doaj.art-0a672d4bf18f4fd9b417ad1a6bde68cb |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T23:26:23Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0a672d4bf18f4fd9b417ad1a6bde68cb2023-11-19T07:56:31ZengMDPI AGCancers2072-66942023-08-011517434810.3390/cancers15174348Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective StudyKazunari Tanaka0Kunihiko Tsuji1Atsushi Hiraoka2Toshifumi Tada3Masashi Hirooka4Kazuya Kariyama5Joji Tani6Masanori Atsukawa7Koichi Takaguchi8Ei Itobayashi9Shinya Fukunishi10Toru Ishikawa11Kazuto Tajiri12Hironori Ochi13Hidenori Toyoda14Chikara Ogawa15Takashi Nishimura16Takeshi Hatanaka17Satoru Kakizaki18Noritomo Shimada19Kazuhito Kawata20Atsushi Naganuma21Hisashi Kosaka22Tomomitsu Matono23Hidekatsu Kuroda24Yutaka Yata25Hideko Ohama26Fujimasa Tada27Kazuhiro Nouso28Asahiro Morishita29Akemi Tsutsui30Takuya Nagano31Norio Itokawa32Tomomi Okubo33Taeang Arai34Keisuke Yokohama35Hiroki Nishikawa36Michitaka Imai37Yohei Koizumi38Shinichiro Nakamura39Hiroko Iijima40Masaki Kaibori41Yoichi Hiasa42Takashi Kumada43Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo 006-8555, JapanCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo 006-8555, JapanGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, JapanDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji 670-8540, JapanDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon 791-0295, JapanDepartment of Hepatology, Okayama City Hospital, Okayama 700-0962, JapanDepartment of Gastroenterology and Hepatology, Kagawa University, Kagawa 761-0795, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, JapanDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, JapanDepartment of Gastroenterology, Asahi General Hospital, Asahi 289-2511, JapanDepartment of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, JapanDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata 950-1104, JapanDepartment of Gastroenterology, Toyama University Hospital, Toyama 930-0194, JapanCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama 790-8524, JapanDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki 503-8502, JapanDepartment of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu 760-0017, JapanDepartment of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya 663-8501, JapanDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, JapanDepartment of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, JapanDivision of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa 277-0863, JapanHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu 565-0871, JapanDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, JapanDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, JapanDepartment of Hepatology, St. Mary’s Hospital, Himeji 670-0801, JapanDivision of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka 020-8505, JapanDepartment of Gastroenterology, Hanwa Memorial Hospital, Osaka 558-0041, JapanGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, JapanGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, JapanDepartment of Hepatology, Okayama City Hospital, Okayama 700-0962, JapanDepartment of Gastroenterology and Hepatology, Kagawa University, Kagawa 761-0795, JapanDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, JapanDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, JapanDepartment of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, JapanDepartment of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, JapanDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata 950-1104, JapanDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon 791-0295, JapanDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji 670-8540, JapanDepartment of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya 663-8501, JapanDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, JapanDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon 791-0295, JapanDepartment of Nursing, Gifu Kyoritsu University, Ogaki 503-8550, JapanAim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in predicting the prognosis and therapeutic efficacy in hepatocellular carcinoma (HCC) patients administered atezolizumab plus bevacizumab (Atez/Bev) as first-line treatment. Materials/Methods: The study period covered September 2020 to December 2022 and involved 371 HCC patients treated with Atez/Bev. The values of the TMs AFP, AFP-L3, and DCP were measured upon introducing Atez/Bev. Elevations in the values of AFP (≥100 ng/mL), AFP-L3 (≥10%), and DCP (≥100 mAU/mL) were considered to indicate a positive TM. The number of positive TMs was summed up and used as the TM score, as previously proposed. Hepatic reserve function was assessed using the modified albumin–bilirubin grade (mALBI). Predictive values for prognosis were evaluated retrospectively. Results: A TM score of 0 was shown in 81 HCC patients (21.8%), 1 in 110 (29.6%), 2 in 112 (29.9%), and 3 in 68 (18.3%). The median overall survival (OS) times for TM scores 0, 1, 2, and 3 were not applicable [NA] (95% CI NA-NA), 24.0 months (95% CI 17.8-NA), 16.7 months (95% CI 17.8-NA), and NA (95% CI 8.3-NA), respectively (<i>p</i> < 0.001). The median progression-free survival (PFS) times for TM scores 0, 1, 2, and 3 were 16.5 months (95% CI 8.0-not applicable [NA]), 13.8 months (95% CI 10.6–21.3), 7.7 months (95% CI 5.3–8.9), and 5.8 months (95% CI 3.0–7.6), respectively (<i>p</i> < 0.001). OS was well stratified in mALBI 1/2a and mALBI 2a/2b. PFS was well stratified in mALBI 2a/2b, but not in mALBI 1/2a. Conclusions: The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as first-line treatment.https://www.mdpi.com/2072-6694/15/17/4348hepatocellular carcinomatumor makeratezolizumab plus bevacizumabprognosispredictive model |
| spellingShingle | Kazunari Tanaka Kunihiko Tsuji Atsushi Hiraoka Toshifumi Tada Masashi Hirooka Kazuya Kariyama Joji Tani Masanori Atsukawa Koichi Takaguchi Ei Itobayashi Shinya Fukunishi Toru Ishikawa Kazuto Tajiri Hironori Ochi Hidenori Toyoda Chikara Ogawa Takashi Nishimura Takeshi Hatanaka Satoru Kakizaki Noritomo Shimada Kazuhito Kawata Atsushi Naganuma Hisashi Kosaka Tomomitsu Matono Hidekatsu Kuroda Yutaka Yata Hideko Ohama Fujimasa Tada Kazuhiro Nouso Asahiro Morishita Akemi Tsutsui Takuya Nagano Norio Itokawa Tomomi Okubo Taeang Arai Keisuke Yokohama Hiroki Nishikawa Michitaka Imai Yohei Koizumi Shinichiro Nakamura Hiroko Iijima Masaki Kaibori Yoichi Hiasa Takashi Kumada Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study Cancers hepatocellular carcinoma tumor maker atezolizumab plus bevacizumab prognosis predictive model |
| title | Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study |
| title_full | Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study |
| title_fullStr | Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study |
| title_full_unstemmed | Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study |
| title_short | Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study |
| title_sort | usefulness of tumor marker score for predicting the prognosis of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab a multicenter retrospective study |
| topic | hepatocellular carcinoma tumor maker atezolizumab plus bevacizumab prognosis predictive model |
| url | https://www.mdpi.com/2072-6694/15/17/4348 |
| work_keys_str_mv | AT kazunaritanaka usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT kunihikotsuji usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT atsushihiraoka usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT toshifumitada usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT masashihirooka usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT kazuyakariyama usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT jojitani usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT masanoriatsukawa usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT koichitakaguchi usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT eiitobayashi usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT shinyafukunishi usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT toruishikawa usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT kazutotajiri usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT hironoriochi usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT hidenoritoyoda usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT chikaraogawa usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT takashinishimura usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT takeshihatanaka usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT satorukakizaki usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT noritomoshimada usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT kazuhitokawata usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT atsushinaganuma usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT hisashikosaka usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT tomomitsumatono usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT hidekatsukuroda usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT yutakayata usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT hidekoohama usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT fujimasatada usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT kazuhironouso usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT asahiromorishita usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT akemitsutsui usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT takuyanagano usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT norioitokawa usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT tomomiokubo usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT taeangarai usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT keisukeyokohama usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT hirokinishikawa usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT michitakaimai usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT yoheikoizumi usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT shinichironakamura usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT hirokoiijima usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT masakikaibori usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT yoichihiasa usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy AT takashikumada usefulnessoftumormarkerscoreforpredictingtheprognosisofhepatocellularcarcinomapatientstreatedwithatezolizumabplusbevacizumabamulticenterretrospectivestudy |